Roadshow
AJ201
|
Mechanism of Action |
Project Code |
Indication |
|
Nrf2 Activator |
AJ201 |
PolyQ Neurodegenerative Diseases: Kennedy’s Disease & Huntington’s Disease |
|
HDAC6 Inhibitor |
AJ302 |
Chemotherapy-Induced Peripheral Neuropathy (CIPN) |
|
HDAC6 Inhibitor |
AJ303 |
Fibrotic Diseases, such as IPF |
|
Translation Research |
Pre-candidate |
Undisclosed Indications |
We are committed to advancing innovative therapies that address significant unmet medical needs, including treatment for rare diseases, like Kennedy’s Disease (SBMA).
- Established 2014
- Company AnnJi Pharmaceutical Co., Ltd.
- Telephone 02-23655677
- Email info@ajpharm.com
- Address 16F.-6, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City 115011 , Taiwan
AnnJi is a clinical-stage drug company dedicated to the development of innovative small molecules. Our pipeline targets therapeutic areas with robust market growth potential such as neurology and dermatology diseases. We are committed to advancing innovative therapies that address significant unmet medical needs, including treatment for rare diseases, like Kennedy’s Disease (SBMA).